BioCryst (NASDAQ: BCRX) lifts ORLADEYO U.S. WAC to $48,487.92 per pack

Rhea-AI Filing Summary

BioCryst Pharmaceuticals, Inc. is increasing the U.S. wholesale acquisition cost of its hereditary angioedema treatment ORLADEYO (berotralstat) effective January 9, 2026. The price is rising from $44,484.33 to $48,487.92 per 28-day pack of either the 150mg or 110mg capsules. This change applies to the wholesale acquisition cost, which is a list price used in transactions between the company and its buyers in the United States.

Insights

Biopharma pricing and revenue analyst

BioCryst raises ORLADEYO U.S. list price, potentially lifting revenue per patient.

BioCryst Pharmaceuticals implemented a higher U.S. wholesale acquisition cost for ORLADEYO (berotralstat) on January 9, 2026. The 28-day pack price increased from $44,484.33 to $48,487.92 for both the 150mg and 110mg capsule strengths. This is a list-price change at the wholesale level rather than a change in product formulation or labeling.

For a chronic therapy, a higher list price can raise gross revenue per treated patient, depending on contract terms, rebates, and payer responses. The disclosure focuses only on the wholesale acquisition cost, so net realized pricing and volume effects are not detailed in this excerpt.

The impact will depend on how U.S. payers, pharmacy benefit managers, and patients respond to the new WAC for ORLADEYO. Future company filings may provide more insight into how this pricing action influences product revenue and patient access.

false 0000882796 0000882796 2026-01-09 2026-01-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2026

BioCryst Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-23186	62-1413174
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)

4505 Emperor Blvd., Suite 200

Durham, North Carolina 27703

(Address of Principal Executive Offices) (Zip Code)

(919) 859-1302

(Registrant’s telephone number, including area code)

________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	BCRX	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Effective January 9, 2026, BioCryst Pharmaceuticals, Inc. (the “Company”) is implementing an increase in the wholesale acquisition cost (WAC) for ORLADEYO® (berotralstat) in the United States from $44,484.33 per 28-day pack (of either 150mg or 110mg capsules) to $48,487.92 per 28-day pack (of either 150mg or 110mg capsules).

The information in this Current Report on Form 8-K, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:  January 9, 2026		BioCryst Pharmaceuticals, Inc.
		By:	/s/ Alane Barnes
			Alane Barnes
			Chief Legal Officer

FAQ

What pricing change did BioCryst (BCRX) make for ORLADEYO in the U.S.?

BioCryst Pharmaceuticals increased the U.S. wholesale acquisition cost of ORLADEYO (berotralstat) from $44,484.33 to $48,487.92 per 28-day pack.

When does BioCryst’s new ORLADEYO price take effect?

The higher wholesale acquisition cost for ORLADEYO is effective as of January 9, 2026.

Which ORLADEYO presentations are affected by BioCryst’s price increase?

The new price of $48,487.92 per 28-day pack applies to both the 150mg and 110mg capsule strengths of ORLADEYO in the United States.

Does the BioCryst (BCRX) pricing change relate to ORLADEYO’s formulation?

No formulation changes are described. The disclosure states an increase in the wholesale acquisition cost for existing 150mg and 110mg capsule packs.

Is the ORLADEYO price change specific to the United States market?

Yes. The company specifies that the wholesale acquisition cost increase for ORLADEYO applies in the United States.

What type of price metric did BioCryst change for ORLADEYO?

BioCryst adjusted the wholesale acquisition cost (WAC), which is the list price paid by wholesalers for a 28-day pack of ORLADEYO.